Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
Varenicline is indicated for smoking cessation in adults
The company intends to respond to the two minor observations within the stipulated time
 
        Subscribe To Our Newsletter & Stay Updated